“…Beta-blocking agent propranolol has been used only in few cases of GSD, with the rationale of downregulating the Raf mitogen-activated protein kinase signaling pathway lowering the expression of VEGF-A (81,102,111,131,132). However, more evidence has been found on the role of propranolol in lymphangiomatosis and in hemangiomatosis especially in young patients showing good effectiveness in reducingthe size of the tumor (19,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136).…”